| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10914884 | Molecular Oncology | 2014 | 10 Pages |
Abstract
Level 1B was the RP2D as it provided adequate pharmacodynamic exposure to dovitinib. The G2071A germline variant act as a genetic modifier that renders different tumors sensitive to dovitinib.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Miguel Quintela-Fandino, Maria J. Bueno, Luis Lombardia, Marta Gil, Antonio Gonzalez-Martin, Raul Marquez, Raquel Bratos, Juan Guerra, Eugene Tan, Antonio Lopez, Ramon Colomer, Ramon Salazar,